COMBINATION OF IMMUNOMODULATORY AGENT WITH PD-1 or PD-L1 CHECKPOINT INHIBITORS IN THE TREATMENT OF CANCER

摘要

Methods for treating cancer include administering a therapeutically effective amount of an immunomodulatory agent such as interferon gamma 1b in combination with a therapeutically effective amount of a PD-1 checkpoint inhibitor such as nivolumab or pembrolizumab or a therapeutically effective amount of a PD-L1 checkpoint inhibitor.